FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 [Yahoo! Finance]
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: Yahoo! Finance
Net Loss: Decreased to $284.2 million, or $2.92 per share, improving from a net loss of $293.7 million, or $3.14 per share in FY 2022. China Performance: Roxadustat sales in China grew by 41%, contributing significantly to revenue. Cost Reduction: Execution of a cost reduction plan resulted in $120 million in annualized expense savings. Cash Position: Strong balance sheet with $248.1 million in cash, extending cash runway into 2026. Upcoming Milestones: Key data readouts expected in 2024 for pamrevlumab trials and potential approval for roxadustat in CIA in China. Warning! GuruFocus has detected 7 Warning Signs with FGEN. FibroGen Inc ( NASDAQ:FGEN ) released its 8-K filing on February 26, 2024, detailing its financial results for the fourth quarter and full year of 2023. The biotechnology company, known for its novel therapeutics for serious medical conditions, has reported a year-over-year increase in total net revenue to $147.8 million, marking a 5% growth. This perfor
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- Global Duchenne Muscular Dystrophy Drugs Market Set to Reach $ 5.5 Billion by 2032, With a CAGR of 10.17% Driven by New Product Approvals, Launches, and a Favorable Landscape [Yahoo! Finance]Yahoo! Finance
- FibroGen to Report First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- FibroGen to Report First Quarter 2024 Financial ResultsGlobeNewswire
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology AAcquire Media Monitor
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology GlobeNewswire
FGEN
Earnings
- 2/26/24 - Miss
FGEN
Sec Filings
- 5/2/24 - Form 4
- 4/25/24 - Form ARS
- 4/24/24 - Form DEFA14A
- FGEN's page on the SEC website